TGF‐β signaling pathway blockade combined with continuous epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) treatment could be beneficial in preventing metastasis in patients with NSCLC resistant to erlotinib [256]. Here, EGFR is linked to non-small cell lung carcinoma.